Poteligeo

February 19, 2019

Poteligeo Proves Safe, Effective for ATL Patients in Clinical Setting

News

Poteligeo (mogamulizumab), an approved treatment for relapsed or refractory adult T-cell leukemia-lymphoma (ATL) patients in Japan, is also safe and effective in a real-world clinical setting, a postmarketing surveillance study found. ... Read more

August 9, 2018

Poteligeo Approved in US for Treating 2 Cutaneous T-cell Lymphoma Subtypes

News

Poteligeo (mogamulizumab-kpkc) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides and Sézary syndrome — two types of cutaneous T-cell lymphoma — in patients ... Read more

November 29, 2017November 29, 2017

FDA to Review Mogamulizumab as Treatment for Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) will review the use of mogamulizumab as a treatment for cutaneous T-cell lymphoma (CTCL) in patients who received at least one prior line of ... Read more

November 14, 2017

Potential Treatment for Advanced CTCL, Mogamulizumab, Under Review in Europe

News

The European Medicines Agency (EMA) agreed to review documents supporting the approval of mogamulizumab — an antibody targeting the CCR4 protein — as a treatment for adults with cutaneous T-cell lymphoma (CTCL) who ... Read more

August 19, 2016August 19, 2016

T-cell Lymphoma/Leukemia Patients Eligible for HSCT Cautioned on Use of Poteligeo

News

Patients with adult T-cell leukemia/lymphoma (ATLL) who were treated with Poteligeo (mogamulizumab), an anti-CCR4 monoclonal antibody, may be at higher risk for serious graft-versus-host disease (GvHD)-related complications following allogeneic hematopoietic stem ... Read more